Short answer
Bio-Techne (TECH) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). References February 11, 2026 Form 8-K for officer appointments and compensation arrangements.
Bio-Techne 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- References February 11, 2026 Form 8-K for officer appointments and compensation arrangements
- Executive and director ownership changes reported through SEC Forms 3 or 4
- Proxy materials expected to disclose transaction participants and their security interests
Item 8.01 · Other Events
- Merger litigation emerged: shareholder lawsuit seeks to enjoin the September 23, 2026 vote, creating execution and timing risk
- Multiple demand letters challenge proxy disclosures, though Bio-Techne disputes the allegations and estimates no potential loss
- Supplemental proxy disclosures reveal 2023 Merck indications at $92 to $95 per share versus Bio-Techne trading at $73.76 to $85.98
- Goldman Sachs valuation ranges updated: $58 to $72 discounted cash flow, $49 to $67 reference multiples
- Valuation analysis reflects approximately $200 million debt, $210 million cash, and 157.0 million to 157.8 million fully diluted shares
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bio-Techne 8-K filings
Get the next TECH 8-K as it lands
Follow TECH for push alerts, or ask the research agent what this filing means.